<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5502047 - Treatment for insomnia - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Treatment for insomnia"><meta name="DC.contributor" content="Neil B. Kavey" scheme="inventor"><meta name="DC.contributor" content="Kavey; Neil B." scheme="assignee"><meta name="DC.date" content="1993-3-22" scheme="dateSubmitted"><meta name="DC.description" content="A method for the treatment of chronic insomnia is disclosed which involves the administration of low dosages of a compound selected from the pharmaceutically acceptable forms of doxepin, trimipramine, amitriptyline, trazodone and mixtures hereof."><meta name="DC.date" content="1996-3-26" scheme="issued"><meta name="DC.relation" content="US:3420851" scheme="references"><meta name="DC.relation" content="US:4110438" scheme="references"><meta name="DC.relation" content="US:4434171" scheme="references"><meta name="DC.relation" content="US:5030632" scheme="references"><meta name="citation_reference" content="Archives of General Psychiatry vol. 36 pp. 85 90 (1979)."><meta name="citation_reference" content="Archives of General Psychiatry vol. 36 pp. 85-90 (1979)."><meta name="citation_reference" content="British Journal of Psychiatry vol. 120 pp. 663 672 (1972)."><meta name="citation_reference" content="British Journal of Psychiatry vol. 120 pp. 663-672 (1972)."><meta name="citation_reference" content="Conn, et al; Pattern of use of Antidepressants in . . . Elderly; Journal of Geriatric Psychology Neurol vol. 5(4), 1992 pp. 228 232."><meta name="citation_reference" content="Conn, et al; Pattern of use of Antidepressants in . . . Elderly; Journal of Geriatric Psychology Neurol vol. 5(4), 1992-pp. 228-232."><meta name="citation_reference" content="Drugs, vol. 38 (S1) pp. 25 31 (1989)."><meta name="citation_reference" content="Drugs, vol. 38 (S1) pp. 25-31 (1989)."><meta name="citation_reference" content="European Journal of Clinical Pharmacology, vol. 37 pp. 145 150 (1989)."><meta name="citation_reference" content="European Journal of Clinical Pharmacology, vol. 37 pp. 145-150 (1989)."><meta name="citation_reference" content="Excerpta Medica International Congress Series vol. 150 pp. 824 826 (1968)."><meta name="citation_reference" content="Excerpta Medica International Congress Series vol. 150 pp. 824-826 (1968)."><meta name="citation_reference" content="Journal of Clinical Pharmacology vol. 9(1) pp. 42 45 (1989)."><meta name="citation_reference" content="Journal of Clinical Pharmacology vol. 9(1) pp. 42-45 (1989)."><meta name="citation_reference" content="Journal of Clinical Psychiatry vol. 44 (9 Section 2) pp. 25 28 (1983)."><meta name="citation_reference" content="Journal of Clinical Psychiatry vol. 44 (9 Section 2) pp. 25-28 (1983)."><meta name="citation_reference" content="Journal of Clinical Psychiatry, vol. 51, pp. 298 302 (1990)."><meta name="citation_reference" content="Journal of Clinical Psychiatry, vol. 51, pp. 298-302 (1990)."><meta name="citation_reference" content="Physician s Desk Reference pp. 1310 1311 (1990)."><meta name="citation_reference" content="Physician s Desk Reference pp. 18489 1849 (1990)."><meta name="citation_reference" content="Physician s Desk Reference pp. 2434 2435 (1990)."><meta name="citation_reference" content="Physician&#39;s Desk Reference pp. 1310-1311 (1990)."><meta name="citation_reference" content="Physician&#39;s Desk Reference pp. 18489-1849 (1990)."><meta name="citation_reference" content="Physician&#39;s Desk Reference pp. 2434-2435 (1990)."><meta name="citation_reference" content="Psychopharmacologia vol. 33 pp. 185 202 (1973)."><meta name="citation_reference" content="Psychopharmacologia vol. 33 pp. 185-202 (1973)."><meta name="citation_reference" content="Sleep Study Abstracts Jan. 1972)."><meta name="citation_patent_number" content="US:5502047"><meta name="citation_patent_application_number" content="US:08/034,252"><link rel="canonical" href="http://www.google.com/patents/US5502047"/><meta property="og:url" content="http://www.google.com/patents/US5502047"/><meta name="title" content="Patent US5502047 - Treatment for insomnia"/><meta name="description" content="A method for the treatment of chronic insomnia is disclosed which involves the administration of low dosages of a compound selected from the pharmaceutically acceptable forms of doxepin, trimipramine, amitriptyline, trazodone and mixtures hereof."/><meta property="og:title" content="Patent US5502047 - Treatment for insomnia"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("oS7uU7WeGPXasQSIkYH4Bg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("DEU"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("oS7uU7WeGPXasQSIkYH4Bg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("DEU"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5502047?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5502047"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=SnE-BAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5502047&amp;usg=AFQjCNHO9p7t5pp6J2fEyIRiDeXS4wtI-w" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5502047.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5502047.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5502047" style="display:none"><span itemprop="description">A method for the treatment of chronic insomnia is disclosed which involves the administration of low dosages of a compound selected from the pharmaceutically acceptable forms of doxepin, trimipramine, amitriptyline, trazodone and mixtures hereof....</span><span itemprop="url">http://www.google.com/patents/US5502047?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5502047 - Treatment for insomnia</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5502047 - Treatment for insomnia" title="Patent US5502047 - Treatment for insomnia"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5502047 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/034,252</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Mar 26, 1996</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Mar 22, 1993</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Mar 22, 1993</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5643897">US5643897</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">034252, </span><span class="patent-bibdata-value">08034252, </span><span class="patent-bibdata-value">US 5502047 A, </span><span class="patent-bibdata-value">US 5502047A, </span><span class="patent-bibdata-value">US-A-5502047, </span><span class="patent-bibdata-value">US5502047 A, </span><span class="patent-bibdata-value">US5502047A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Neil+B.+Kavey%22">Neil B. Kavey</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Kavey%3B+Neil+B.%22">Kavey; Neil B.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5502047.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5502047.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5502047.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (4),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (27),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (25),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (10),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (8)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5502047&usg=AFQjCNGkxIDK_oBOhCFDuoYZUChKmHJWeQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5502047&usg=AFQjCNFt6FjqRBoBKI1wfnx6Ms57ASpeAA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5502047A%26KC%3DA%26FT%3DD&usg=AFQjCNFDKWaTc_B-h8QVUFMqnY08jN8AHA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54028451" lang="EN" load-source="patent-office">Treatment for insomnia</invention-title></span><br><span class="patent-number">US 5502047 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37512481" lang="EN" load-source="patent-office"> <div class="abstract">A method for the treatment of chronic insomnia is disclosed which involves the administration of low dosages of a compound selected from the pharmaceutically acceptable forms of doxepin, trimipramine, amitriptyline, trazodone and mixtures hereof.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(5)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5502047-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5502047-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5502047-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5502047-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5502047-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5502047-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5502047-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5502047-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5502047-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5502047-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(10)</span></span></div><div class="patent-text"><div mxw-id="PCLM4950822" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>I claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A method for the treatment of a patient suffering from chronic insomnia comprising administering to said patient a compound selected from the group consisting of doxepin and pharmaceutically acceptable salts thereof in a daily dosage ranging from about 0.5 to about 20 milligrams.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The method of claim 1 wherein the pharmaceutically acceptable salt of doxepin is the hydrochloride salt thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The method of claim 1 where the daily dosage is about 0.5 to about 10 milligrams.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The method of claim 1 where the daily dosage is about 0.5 to about 5 milligrams.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The method of claim 2 where the daily dosage is about 0.5 to about 10 milligrams.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. The method of claim 2 where the daily dosage is about 0.5 to about 5 milligrams.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The method of claim 1 wherein the patient is suffering from depression.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The method of claim 1 wherein the patient is suffering from depression.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. The method of claim 4 wherein the patient is not suffering from depression.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The method of claim 5 wherein the patient is not suffering from depsression.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66768312" lang="EN" load-source="patent-office" class="description">
    <heading>FIELD OF INVENTION</heading> <p>This invention relates to a method for the treatment of individuals suffering from chronic insomnia. In a preferred embodiment, the present invention relates to a method for the treatment of chronic insomnia in individuals other than those suffering from depression.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>A large percentage of the adult population suffers from insomnia in some form at some time in their lives. This may vary from an occasional episode to chronic conditions and may involve onset and/or maintenance insomnia. Chronic insomnia is typically accepted to involve episodes greater than three (3) weeks in duration. The effects of sleep deprivation resulting from such insomnia are well known and need not be described herein other than to say that they are to be avoided.</p>
    <p>Currently, there exist treatments only for acute insomnia. These treatments involve the administration of medication, either of the non-barbiturate or barbiturate type, shortly before bedtime. While both types of sedatives may be used to effectively treat insomnia, neither is without its undesirable side effects. For instance, barbiturate type sedatives, such as secobarbital sodium (sold by Eli Lilly and Company under the tradename of Seconal®) are general depressants. While effective, these medications are well known to lose their effectiveness after a few days. They are further highly addictive and commonly abused. They are therefore no longer widely prescribed.</p>
    <p>The group of medications now most commonly used for the treatment of insomnia are the benzodiazepines. There are now 5 such "hypnotics" commonly used. They differ significantly in half lives but are otherwise very similar and equally effective. They have supplanted the barbiturates as the principal treatment for insomnia because they have slightly less addiction potential and are associated with less risk for suicide than the barbiturates unless taken with alcohol. However, this group, too, is know to be effective only for acute or short term insomnia and the medications are not acceptedly used for chronic insomnia. Furthermore, they are also addictive and their wide usage is drawing increasing concern as their potential side effects become more apparent. These include daytime sedation, decreased cognitive abilities such as memory loss and, most recently in the case of Halcion®(triazolam), agitated behavior.</p>
    <p>The present invention involves the administration of very small doses of specific known psychotherapeutic agents. These agents include tricyclic compounds and a triazolopyridine derivative which are currently prescribed both for the general treatment of depression and for the treatment of the insomnia component of a depression in individuals suffering from severe depression. These compounds are known to possess a sedative effect in such individuals when administered in moderate to large dosages. However, the use of these compounds at the extremely low dosages claimed herein for the successful treatment of chronic insomnia in otherwise healthy individuals has not been reported and is not obvious in view thereof. For example, the compounds used in the present invention are currently prescribed for a 20-60 year old depressed patient population in dosages varying from about 75 to about 300 milligrams per day of the tricyclic compounds and about 150 to about 600 milligrams per day of the triazolopyridine compound. The entire dosage of such medications are often administered at bedtime. In contrast, the method of the present invention involves the use of a small fraction of such dosage.</p>
    <heading>OBJECTS OF THE INVENTION</heading> <p>It is an object of the present invention to develop a method for the successful treatment of chronic insomnia.</p>
    <p>It is another object of the present invention to develop a method for the successful treatment of insomnia in individuals not suffering from depression.</p>
    <p>It is still another object of the present invention to develop a method for the treatment of chronic insomnia using non-addictive medications.</p>
    <p>It is a further object of the present invention to develop a method for the treatment of chronic insomnia which does not involve the adverse effects associated with the currently prescribed hypnotics, i.e. residual sedation, lethargy, drowsiness, loss of cognitive ability and/or agitation.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>The present invention is directed to a method for the treatment of a patient suffering from chronic insomnia comprising administering to said patient a compound selected from the group consisting of the pharmaceutically acceptable forms of doxepin, amitriptyline, trimipramine, trazodone and mixtures thereof. The dosage for administration of doxepin, amitriptyline, trazodone, trimipramine and mixtures thereof ranges from about 0.5 to about 20.0 milligrams.</p>
    <p>In one preferred embodiment of the present invention, the invention is directed to a method for the treatment of a patient suffering from chronic insomnia comprising administering to said patient doxepin, amitriptyline, trimipramine or mixtures thereof in a dosage of about 10 milligrams or less.</p>
    <p>In another preferred embodiment of the present invention, the invention is directed to a method for the treatment of a patient suffering from chronic insomnia comprising administering to said patient trazodone in a dosage of about 15 milligrams or less.</p>
    <p>In yet another embodiment, the present invention is directed to a method for the treatment of chronic insomnia in a patient who is not suffering from depression comprising administering to said patient a compound selected from the group consisting of the pharmaceutically acceptable forms of doxepin, amitriptyline, trimipramine, trazodone and mixtures thereof in a dosage ranging from about 0.5 to about 20 milligrams.</p>
    <heading>DESCRIPTION OF THE INVENTION</heading> <p>The method of the present invention involves the administration of doxepin, amitriptyline, trimipramine, trazodone and mixtures thereof. As noted above, these compounds are well known psychotherapeutic agents which are currently prescribed as antidepressants. Each compound is further readily available commercially. The hydrochloride salt of doxepin is currently marketed by Pfizer Inc. under the tradename Sinequan®. The hydrochloride salt of amitriptyline is currently marketed by Merck &amp; Co., Inc. under the tradename Elavil®. Trimipramine maleate is currently marketed by Wyeth-Ayerst Laboratories under the tradename Surmontil®. The hydrochloride salt of trazodone is currently marketed by Mead Johnson Pharmaceuticals under the tradename Desyrel®.</p>
    <p>Of the above compounds which are commercially available as a hydrochloride salt or a maleate in the case of trimipramene, it should be understood that the use of other pharmaceutical salts of such compounds are also within the practice of the present invention. Furthermore, although the above compounds are commercially available in various forms, use of these compounds in other than currently administratable forms (e.g. injectable solutions, capsules, caplets) is also within the scope of the present invention.</p>
    <p>As stated above, dosages of doxepin, amitriptyline, trimipramine or mixtures thereof may vary from about 0.5 to about 20.0 milligrams. Preferably dosages of about 10 milligrams or less are utilized. Most preferably, dosages of about 5 milligrams or less are utilized. With respect to trazodone, dosages of about 0.5 to about 20 milligrams are used. Preferably, dosages of about 15 milligrams or less are used. However, as it is recognized that each individual may react differently to a given dose of the medication used herein, the dosages recited herein should be accorded flexibility. Since the point of the present invention is to induce and maintain normal sleep without exposing the patient to residual effect of medication, the lowest effective dosage of the compounds are to be utilized whenever possible.</p>
    <p>Administration of the compounds should take place within about one hour before bedtime. Again, the onset of the sedative effect will vary with the individual and the dosage prescribed.</p>
    <p>"Depression" as used herein refers to a psychiatric diagnosis of depression and includes those disorders categorized under depression in the Psychiatric Diagnostic and Statistical Manual 3, American Psychiatric Association Press.</p>
    <p>The following Examples are offered to illustrate the claimed method and its practice. They should not however be construed in any way as a limitation to the scope of the present invention.</p>
    <heading>EXAMPLE 1</heading> <p>The patient was a thirty-eight year old female who suffered from maintenance insomnia for one year. She had been treated previously with "hypnotics" and, at the time of presentation, was using diphenhydramine 50-100 mg hs without success. Psychotherapy had also failed to relieve the insomnia. At the time of consultation, she had normal affect with no depression, anxiety or substance overuse. She was started on doxepin 10 mg hs. Follow up at 30 days revealed her to be sleeping well. An attempt to decrease the dosage produced a return of the insomnia. She is currently maintained on 10 mg of doxepin and is doing well.</p>
    <heading>EXAMPLE 2</heading> <p>The patient was a fifty-two year old female with a maintenance insomnia of three years' duration. She had tried several therapeutic modalities including dalmane 15 mg hs, hypnosis, and a behavioral program all without improvement. At the time of presentation, affect was normal and there was no depression or anxiety. Alcohol use was not a factor. She was prescribed doxepin 5 mg hs which produced an immediate resolution of the disturbed sleep. The doxepin was subsequently discontinued and the insomnia returned. She was restarted on doxepin at 5 mg hs and the insomnia again was relieved. Maintenance is ongoing at this dosage.</p>
    <heading>EXAMPLE 3</heading> <p>The patient was a fifty-two year old male with a longstanding maintenance insomnia. He had been treated with temazepam 15 mg hs for many years but was suffering memory loss and had a fear of addiction. Clinical evaluation revealed normal affect without depression, anxiety, or substance use. He was started on doxepin 10 mg hs which rapidly restored sound, uninterrupted sleep. An attempt to lower the dosage ended with a return of the insomnia. The dosage level was increased back to 10 mg with resolution of the sleep disturbance. He is currently maintained at that dosage and is doing well.</p>
    <heading>EXAMPLE 4</heading> <p>The patient was a forty-nine year old female with a maintenance insomnia of two years'duration. She had previously been treated with diazepam for anxiety and the insomnia with no effect on the latter. She had a past history of depression but had normal affect and no depression at her initial consultation or during her treatment. Alcohol use was not significant. She was started on doxepin 12.5 mg hs upon which the insomnia was resolved. At long term follow up there was no sleep complaint at this dosage.</p>
    <heading>EXAMPLE 5</heading> <p>The patient was a sixty-five year old male retiree with an onset and maintenance insomnia of thirty years' duration. He had attempted self-treatment unsuccessfully with several over-the-counter preparations. Prescription "sleeping pills" has been similarly ineffective. At the time of presentation, the patient had a normal affect with no anxiety, depression, or substance abuse. Therapy was initiated with doxepin 10 mg hs which effected undisturbed and restful sleep. He is now maintained on doxepin 8 mg hs and is doing well.</p>
    <heading>EXAMPLE 6</heading> <p>The patient was a fifty-four year old male who had developed a maintenance insomnia. He had been previously treated with alprazolam 0,125 mg hs without improvement. A behavioral program combined with attempted withdrawal from the alprazolam was ineffective. Clinical evaluation revealed a normal affect and mental status, and an absence of depression, anxiety and substance abuse. He was started on doxepin 5 mg hs which produced a clinical cure. After two years at this dosage, he continues to sleep well and has experienced no adverse effects from the medication.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3420851">US3420851</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 19, 1962</td><td class="patent-data-table-td patent-date-value">Jan 7, 1969</td><td class="patent-data-table-td ">Pfizer &amp; Co C</td><td class="patent-data-table-td ">Novel dibenzoxepines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4110438">US4110438</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 21, 1977</td><td class="patent-data-table-td patent-date-value">Aug 29, 1978</td><td class="patent-data-table-td ">American Home Products Corporation</td><td class="patent-data-table-td ">Luteinizing hormone-releasing hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4434171">US4434171</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 23, 1981</td><td class="patent-data-table-td patent-date-value">Feb 28, 1984</td><td class="patent-data-table-td ">Sandoz Ltd.</td><td class="patent-data-table-td ">Neuroleptic, antidepressant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5030632">US5030632</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 17, 1990</td><td class="patent-data-table-td patent-date-value">Jul 9, 1991</td><td class="patent-data-table-td ">Sandoz Pharm. Corp.</td><td class="patent-data-table-td ">Low dose temazepam</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Archives of General Psychiatry vol. 36 pp. 85 90 (1979).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Archives of General Psychiatry vol. 36 pp. 85-90 (1979).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">British Journal of Psychiatry vol. 120 pp. 663 672 (1972).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">British Journal of Psychiatry vol. 120 pp. 663-672 (1972).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Conn, et al; Pattern of use of Antidepressants in . . . Elderly; Journal of Geriatric Psychology Neurol vol. 5(4), 1992 pp. 228 232.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Conn, et al; Pattern of use of Antidepressants in . . . Elderly; Journal of Geriatric Psychology Neurol vol. 5(4), 1992-pp. 228-232.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Drugs, vol. 38 (S1) pp. 25 31 (1989).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Drugs, vol. 38 (S1) pp. 25-31 (1989).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">European Journal of Clinical Pharmacology, vol. 37 pp. 145 150 (1989).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">European Journal of Clinical Pharmacology, vol. 37 pp. 145-150 (1989).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Excerpta Medica International Congress Series vol. 150 pp. 824 826 (1968).</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Excerpta Medica International Congress Series vol. 150 pp. 824-826 (1968).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Journal of Clinical Pharmacology vol. 9(1) pp. 42 45 (1989).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Clinical Pharmacology vol. 9(1) pp. 42-45 (1989).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Journal of Clinical Psychiatry vol. 44 (9 Section 2) pp. 25 28 (1983).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Clinical Psychiatry vol. 44 (9 Section 2) pp. 25-28 (1983).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Journal of Clinical Psychiatry, vol. 51, pp. 298 302 (1990).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Clinical Psychiatry, vol. 51, pp. 298-302 (1990).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Physician s Desk Reference pp. 1310 1311 (1990).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Physician s Desk Reference pp. 18489 1849 (1990).</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Physician s Desk Reference pp. 2434 2435 (1990).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Physician's Desk Reference pp. 1310-1311 (1990).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Physician's Desk Reference pp. 18489-1849 (1990).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Physician's Desk Reference pp. 2434-2435 (1990).</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Psychopharmacologia vol. 33 pp. 185 202 (1973).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Psychopharmacologia vol. 33 pp. 185-202 (1973).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Sleep Study Abstracts Jan. 1972).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5643897">US5643897</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 25, 1996</td><td class="patent-data-table-td patent-date-value">Jul 1, 1997</td><td class="patent-data-table-td ">Kavey; Neil B.</td><td class="patent-data-table-td ">Amitriptyline, trimipramine, trazodone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6211229">US6211229</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 17, 2000</td><td class="patent-data-table-td patent-date-value">Apr 3, 2001</td><td class="patent-data-table-td ">Neil B. Kavey</td><td class="patent-data-table-td ">Administering doxepin, amitripyline, trimipramine, trazodone and mixtures for sleep aids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7189757">US7189757</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 16, 2002</td><td class="patent-data-table-td patent-date-value">Mar 13, 2007</td><td class="patent-data-table-td ">Hypnion, Inc.</td><td class="patent-data-table-td ">Sleep disorders; side effect reduction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7345096">US7345096</a></td><td class="patent-data-table-td patent-date-value">Oct 14, 2003</td><td class="patent-data-table-td patent-date-value">Mar 18, 2008</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7365076">US7365076</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td patent-date-value">Apr 29, 2008</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7402698">US7402698</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td patent-date-value">Jul 22, 2008</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">1-[2-(benzylamino)-1-(3,4-dichlorophenyl)ethyl]cyclobutanol hydrochloride; norepinephrine reuptake inhibitor; antidepressant, analgesic; vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, sleep disorder, hormone replacement syndrome</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7414052">US7414052</a></td><td class="patent-data-table-td patent-date-value">Mar 28, 2005</td><td class="patent-data-table-td patent-date-value">Aug 19, 2008</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">1-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)-3-(methylamino)-1-phenylpropan-2-ol; fluctuations of sex steroid lelels; monoamine reuptake modulator; antidepressant, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue and fibromylagia syndrome, stress and urinary incontinence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7419980">US7419980</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td patent-date-value">Sep 2, 2008</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">Treating conditions improved by monoamine reuptake; 1-[1-(2-naphthyl)-2-piperazin-1-ylethyl]cyclobutanol; sexual disorders, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, hot flashes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7491723">US7491723</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td patent-date-value">Feb 17, 2009</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">Alkanol and cycloalkanol-amine derivatives and methods of their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7517899">US7517899</a></td><td class="patent-data-table-td patent-date-value">Mar 28, 2005</td><td class="patent-data-table-td patent-date-value">Apr 14, 2009</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">Phenylaminopropanol derivatives and methods of their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7524846">US7524846</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td patent-date-value">Apr 28, 2009</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">heterocylcyclic amines used for treating or preventing conditions ameliorated by monoamine reuptake such as vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7531543">US7531543</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td patent-date-value">May 12, 2009</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">Phenylpiperazine cycloalkanol derivatives and methods of their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7550456">US7550456</a></td><td class="patent-data-table-td patent-date-value">Feb 14, 2008</td><td class="patent-data-table-td patent-date-value">Jun 23, 2009</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorder</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7550485">US7550485</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td patent-date-value">Jun 23, 2009</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">Conditions ameliorated by monoamine reuptake such as hot flashes, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; e.g. 1-[2-(1,4&#39;-bipiperidin-1&#39;-yl)-1-(3-chlorophenyl)ethyl]cyclohexanol dihydrochloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7629378">US7629378</a></td><td class="patent-data-table-td patent-date-value">Feb 18, 2004</td><td class="patent-data-table-td patent-date-value">Dec 8, 2009</td><td class="patent-data-table-td ">Gideon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antiallergens; analgesics; using doxepin, or isomer thereof; side effect reduction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7638512">US7638512</a></td><td class="patent-data-table-td patent-date-value">Jun 23, 2008</td><td class="patent-data-table-td patent-date-value">Dec 29, 2009</td><td class="patent-data-table-td ">Wyeth</td><td class="patent-data-table-td ">Phenylaminopropanol derivatives and methods of their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7772275">US7772275</a></td><td class="patent-data-table-td patent-date-value">Feb 17, 2009</td><td class="patent-data-table-td patent-date-value">Aug 10, 2010</td><td class="patent-data-table-td ">Gideon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and method for treating affective, painful or allergic disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7915307">US7915307</a></td><td class="patent-data-table-td patent-date-value">Jul 20, 2007</td><td class="patent-data-table-td patent-date-value">Mar 29, 2011</td><td class="patent-data-table-td ">Somaxon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods of improving the pharmacokinetics of doxepin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7935714">US7935714</a></td><td class="patent-data-table-td patent-date-value">May 13, 2005</td><td class="patent-data-table-td patent-date-value">May 3, 2011</td><td class="patent-data-table-td ">Bright Future Pharmaceutical Laboratories</td><td class="patent-data-table-td ">Compositions for sleeping disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8513299">US8513299</a></td><td class="patent-data-table-td patent-date-value">May 18, 2007</td><td class="patent-data-table-td patent-date-value">Aug 20, 2013</td><td class="patent-data-table-td ">Pernix Sleep, Inc.</td><td class="patent-data-table-td ">Sleep efficiency</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110178166">US20110178166</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 22, 2010</td><td class="patent-data-table-td patent-date-value">Jul 21, 2011</td><td class="patent-data-table-td ">Somaxon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods of using low-dose doxepin for the improvement of sleep</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110318412">US20110318412</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 18, 2007</td><td class="patent-data-table-td patent-date-value">Dec 29, 2011</td><td class="patent-data-table-td ">Somaxon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004035036A1?cl=en">WO2004035036A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 15, 2003</td><td class="patent-data-table-td patent-date-value">Apr 29, 2004</td><td class="patent-data-table-td ">Darlene Coleman Deecher</td><td class="patent-data-table-td ">A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008052139A2?cl=en">WO2008052139A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 25, 2007</td><td class="patent-data-table-td patent-date-value">May 2, 2008</td><td class="patent-data-table-td ">Somaxon Pharmaceuticals Inc</td><td class="patent-data-table-td ">Ultra low dose doxepin and methods of using the same to treat sleep disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008070795A2?cl=en">WO2008070795A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 6, 2007</td><td class="patent-data-table-td patent-date-value">Jun 12, 2008</td><td class="patent-data-table-td ">Somaxon Pharmaceuticals Inc</td><td class="patent-data-table-td ">Combination therapy using low-dose doxepin for the improvement of sleep</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S183000">514/183</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S453000">514/453</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S923000">514/923</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S450000">514/450</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031496000">A61K31/496</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/496">A61K31/496</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/00">A61K31/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SnE-BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/923">Y10S514/923</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/496</span>, <span class="nested-value">A61K31/00</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">May 3, 2007</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 4, 2006</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 1-7, 9 AND 10 ARE CANCELLED. CLAIM 8 IS DETERMINED TO BE PATENTABLE AS AMENDED. NEW CLAIMS 11-25 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 6, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040225</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 16, 2003</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 4, 2000</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PROCOM ONE, INC., COLORADO</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KAVEY, NEIL B.;REEL/FRAME:011410/0188</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20000731</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PROCOM ONE, INC. P.O. BOX 881117 STEAMBOAT SPRINGS</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 29, 1999</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 29, 1999</td><td class="patent-data-table-td ">SULP</td><td class="patent-data-table-td ">Surcharge for late payment</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 19, 1999</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2CzS40wnrfGv8PK5yt7jQPrAK0Ew\u0026id=SnE-BAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U1bPNrXjbJKKb3T6_PX3_MamPA7XQ\u0026id=SnE-BAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3IXOxruwVEsWvbZ_jSwMZRp4MyNA","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Treatment_for_insomnia.pdf?id=SnE-BAABERAJ\u0026output=pdf\u0026sig=ACfU3U0LHcNik2jK8WGTgdqoLfKVR5uggQ"},"sample_url":"http://www.google.com/patents/reader?id=SnE-BAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>